Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jul 22:12:696087.
doi: 10.3389/fendo.2021.696087. eCollection 2021.

Insulin Treatment May Increase Adverse Outcomes in Patients With COVID-19 and Diabetes: A Systematic Review and Meta-Analysis

Yan Yang  1 , Zixin Cai  1 , Jingjing Zhang  1
Affiliations
Meta-Analysis

Insulin Treatment May Increase Adverse Outcomes in Patients With COVID-19 and Diabetes: A Systematic Review and Meta-Analysis

Yan Yang et al. Front Endocrinol (Lausanne). .

Abstract

Background and objective: Recently, insulin treatment has been found to be associated with increased mortality and other adverse outcomes in patients with coronavirus disease 2019 (COVID-19) and diabetes, but the results remain unclear and controversial, therefore, we conducted this meta-analysis.

Methods: Four databases, namely, PubMed, Web of Science, EMBASE and the Cochrane Library, were used to identify all studies concerning insulin treatment and the adverse effects of COVID-19, including mortality, incidence of severe/critical complications, in-hospital admission and hospitalization time. To assess publication bias, funnel plots, Begg's tests and Egger's tests were used. The odds ratios (ORs) with 95% confidence intervals (CIs) were used to access the effect of insulin therapy on mortality, severe/critical complications and in-hospital admission. The association between insulin treatment and hospitalization time was calculated by the standardized mean difference (SMD) with 95% CIs.

Results: Eighteen articles, involving a total of 12277 patients with COVID-19 and diabetes were included. Insulin treatment was significantly associated with an increased risk of mortality (OR=2.10; 95% CI, 1.51-2.93) and incidence of severe/critical COVID-19 complications (OR=2.56; 95% CI, 1.18-5.55). Moreover, insulin therapy may increase in-hospital admission in patients with COVID-19 and diabetes (OR=1.31; 95% CI, 1.06-1.61). However, there was no significant difference in the hospitalization time according to insulin treatment (SMD=0.21 95% CI, -0.02-0.45).

Conclusions: Insulin treatment may increase mortality and severe/critical complications in patients with COVID-19 and diabetes, but more large-scale studies are needed to confirm and explore the exact mechanism.

Keywords: COVID-19; adverse outcomes; complications; diabetes; insulin treatment; mortality.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of the study selection process.
Figure 2
Figure 2
Forest plots of OR for the association between the insulin treatment and the mortality of COVID-19.
Figure 3
Figure 3
Funnel plot of the association between the insulin treatment and the mortality (A), complications (B), and the in-hospital admission (C) of COVID-19.
Figure 4
Figure 4
Sensitivity analysis for the effect insulin treatment on the mortality (A), complications (B), and the in-hospital admission (C) of COVID-19.
Figure 5
Figure 5
Forest plots of OR for the association between the insulin treatment and the complications of COVID-19.
Figure 6
Figure 6
Forest plots of OR for the overall result (A) and subgroup analysis based on type of diabetes (B) of the association between the insulin treatment and the in-hospital admission of COVID-19.
Figure 7
Figure 7
Forest plots of SMD for the association between the insulin treatment and the hospitalization time of COVID-19.
See this image and copyright information in PMC

References

    1. Bhadade R, Harde M, deSouza R, Kasbe A, Deshpande C, Dave S, et al. . Appraisal of Critically Ill COVID-19 Patients at a Dedicated COVID Hospital The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. J Assoc Phys India (2020) 68(9):14–9. 10.1016/s2213-8587(20)30271-0 - DOI - PubMed
    1. Abu-Farha M, Al-Mulla F, Thanaraj TA, Kavalakatt S, Ali H, Abdul Ghani M, et al. . Impact of Diabetes in Patients Diagnosed With COVID-19. Front Immunol (2020) 11:576818. 10.3389/fimmu.2020.576818 - DOI - PMC - PubMed
    1. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. . Association of Blood Glucose Control and Outcomes in Patients With COVID-19 and Pre-Existing Type 2 Diabetes. Cell Metab (2020) 31(6):1068–77.e1063. 10.1016/j.cmet.2020.04.021 - DOI - PMC - PubMed
    1. Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, et al. . Fasting Blood Glucose at Admission is an Independent Predictor for 28-Day Mortality in Patients With COVID-19 Without Previous Diagnosis of Diabetes: A Multi-Centre Retrospective Study. Diabetologia (2020) 63(10):2102–11. 10.1007/s00125-020-05209-1 - DOI - PMC - PubMed
    1. Lee MH, Wong C, Ng CH, Yuen DCW, Lim AYL, Khoo CM. Effects of Hyperglycaemia on Complications of COVID-19: A Meta-Analysis of Observational Studies. Diabetes Obes Metab (2021) 23(1):287–9. 10.1111/dom.14184 - DOI - PubMed

Publication types